证券代码：300436 证券简称：广生堂 公告编号：2025076 福建广生堂药业股份有限公司 关于 2025 年第三次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 11 月 21 日（星期五）14:30 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 21 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 21 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会 ...

国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年第三次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年十一月 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 2025 年第三次临时股东大会之法律意见书 致：福建广生堂药业股份有限公司 福建广生堂药业股份有限公司（以下简称"公司"）2025 年第三次临时股东 大会于 2025 年 11 月 21 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师出席现场会议，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 等法律、法规及中国证券监督 ...

Core Insights - The article provides an overview of the latest net asset value (NAV) rankings of various funds, highlighting the top-performing and bottom-performing funds in the market [2][4]. Fund Performance Summary Top 10 Funds by NAV Growth - The top 10 funds with the highest NAV growth as of November 17, 2025, include: 1. 东方阿尔法瑞享混合发起C: NAV 1.1144, growth 6.24% 2. 东方阿尔法瑞享混合发起A: NAV 1.1144, growth 6.22% 3. 泰信发展主题混合: NAV 2.0350, growth 4.90% 4. 泰信现代服务业混合: NAV 2.2980, growth 4.64% 5. 圆信永丰高端制造C: NAV 3.0301, growth 4.59% 6. 圆信永丰高端制造A: NAV 3.0304, growth 4.59% 7. 国寿安保低碳经济混合A: NAV 1.1454, growth 4.26% 8. 国寿安保低碳经济混合C: NAV 1.1336, growth 4.26% 9. 创金合信全球医药生物股票发起(QDII)A: NAV 1.6867, growth 4.20% 10. 创金合信全球医药生物股票发起(QDII)C: NAV 1.6721, growth 4.20% [2]. Bottom 10 Funds by NAV Decline - The bottom 10 funds with the largest NAV declines as of November 17, 2025, include: 1. 同泰大健康主题混合C: NAV 0.4961, decline -3.58% 2. 同泰大健康主题混合A: NAV 0.5053, decline -3.57% 3. 国投瑞银白银期货(LOF)C: NAV 1.3605, decline -3.56% 4. 国投瑞银白银期货(LOF)A: NAV 1.3718, decline -3.56% 5. 景顺长城医疗产业股票C: NAV 1.3737, decline -3.32% 6. 景顺长城医疗产业股票A: NAV 1.3777, decline -3.32% 7. 华富健康文娱灵活配置混合C: NAV 1.1653, decline -3.24% 8. 华富健康文娱灵活配置混合A: NAV 1.1750, decline -3.24% 9. 银华成长智选混合A: NAV 1.0716, decline -3.13% 10. 银华成长智选混合C: NAV 1.0694, decline -3.13% [4]. Market Analysis - The Shanghai Composite Index showed a downward trend, while the ChiNext Index experienced fluctuations, closing slightly lower. The total trading volume reached 1.93 trillion, with a market breadth of 2,584 gainers to 2,726 losers [6]. - The leading sectors included software services with gains exceeding 2%, while the lagging sectors were pharmaceuticals, insurance, healthcare, banking, construction materials, and securities [6]. Fund Strategy Insights - The top-performing fund, 泰信发展主题混合, is focused on the new energy sector, with a significant portion of its holdings in lithium mining companies, indicating a strong performance relative to the market [7]. - Conversely, the poorly performing fund, 同泰大健康主题混合C, is concentrated in the pharmaceutical sector, which has faced significant declines in its top holdings [7].

Group 1 - The CITIC Pharmaceutical Index increased by 3.29%, outperforming the CSI 300 Index by 4.37 percentage points, ranking 3rd among 30 primary industries [1] - The top ten stocks with the highest gains this week include Jindike, Renmin Tongtai, Chengda Pharmaceutical, Hefuchina, Fuxiang Pharmaceutical, Te Yi Pharmaceutical, Yao Yigou, Bohui Innovation, Shuyupingmin, and Haichen Pharmaceutical [1] - The top ten stocks with the largest declines this week include *ST Changyao, Zhend Medical, Heyuan Biological-U, Weigao Blood Purification, Furui Shares, Ruimaite, Microelectrophysiology, Botuo Biological, Bibete-U, and Shuoshi Biological [1] Group 2 - On November 10, Guangshentang Pharmaceutical's core drug, the oral small molecule hepatitis B surface antigen inhibitor GST-HG131, had its Phase II clinical data selected for the AASLD annual meeting's latest breakthrough summary and was reported on-site [1] - GST-HG131 is the first oral drug in global hepatitis B clinical breakthrough research that significantly reduces HBsAg in hepatitis B patients, with 76.5% of patients achieving levels below 100 IU/ml within three months, attracting attention from many multinational pharmaceutical companies for potential collaboration [1] Group 3 - On November 10, Roche announced that its third-generation BTK inhibitor Fenebrutinib met primary endpoints in two Phase III studies (FENhance 2 and FENtrepid) for treating relapsing multiple sclerosis (RMS) [2] - Results showed that at week 96, the annualized relapse rate (ARR) for patients on Fenebrutinib was significantly lower compared to those on teriflunomide, and at week 120, Fenebrutinib was non-inferior to Ocrevus in delaying disability progression in primary progressive multiple sclerosis (PPMS) patients [2] - Pfizer announced the successful completion of its $9.2 billion acquisition of Metsera, a biopharmaceutical company focused on developing next-generation treatments for obesity and cardiovascular metabolic diseases [2] - This acquisition adds a series of potential candidates highly complementary to Pfizer's existing internal medicine pipeline, including MET-097i, a weekly or monthly injectable GLP-1 receptor agonist entering Phase III trials, and MET-233i, a monthly amylin analog currently in Phase I evaluation [2]

Core Viewpoint - The article focuses on the innovative pipeline layout of Xinlitai in the CKM (Cardio-Kidney-Metabolic) field, emphasizing the company's strategic focus on chronic diseases related to cardiovascular health, kidney function, and metabolic disorders [13][18]. Market Review - The CITIC Pharmaceutical Index rose by 3.29%, outperforming the CSI 300 Index by 4.37 percentage points, ranking third among CITIC's 30 primary industries [8]. - The top ten stocks by growth this week included Jindike, Renmin Tongtai, and Chengda Pharmaceutical, while the bottom ten included *ST Changyao and Zhendai Medical [8]. Overall Perspective and Investment Themes - The innovative drug sector is transitioning from a quantity-driven logic to a quality-driven logic, with a focus on differentiated and internationalized pipelines expected to yield profitable products by 2025 [10]. - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, and the home medical device market is benefiting from subsidy policies [10]. - The CXO and life sciences services sector is anticipated to see a rebound in domestic financing, with a trend towards high growth expected to return [10]. - The pharmaceutical industry is expected to enter a new growth cycle, particularly in the specialty raw materials sector, with a focus on patent expirations and vertical expansion of formulations [10]. Company-Specific Insights - Xinlitai currently has six innovative drugs on the market, with innovative drug revenue expected to exceed 50% by the end of 2025, driven by strong growth in products like Xinlitai and Fuli [12][16]. - The company is focusing on a comprehensive pipeline addressing various stages of CKM syndrome, with over 50 products in development targeting cardiovascular diseases, chronic kidney disease, and metabolic disorders [17][21]. - Xinlitai's internationalization strategy includes establishing a subsidiary in the U.S. (Salubris Bio) to enhance its global competitive edge [30]. Pipeline Development - The CKM pipeline includes drugs targeting obesity, hypertension, and chronic kidney disease, with a focus on innovative mechanisms and new targets for lipid management [25][27]. - The company is advancing multiple projects in various clinical phases, with significant milestones expected in the coming years [29][34]. Investment Recommendations - The medical device sector is expected to benefit from a recovery in bidding for imaging equipment and the growth of home medical devices due to government subsidies [40]. - The life sciences services sector is showing signs of recovery, with increasing demand and a focus on domestic product replacement [46].

Group 1 - The company emphasizes the clinical value and market potential of TAEST16001 and is actively advancing the preparatory phase for confirmatory clinical trials [1] - The company has previously disclosed progress in the new drug development stage and will continue to announce updates based on clinical situations in accordance with information disclosure rules [1] - Investors have raised concerns regarding the lack of transparency about the enrollment status of the confirmatory clinical trial, questioning why the company has not provided clear updates [3] Group 2 - The company has received recognition from the CDE for the confirmatory clinical trial plan for TAEST16001, but has not publicly disclosed whether the first patient has been enrolled [3] - Investors are demanding clarity on the enrollment status, indicating that this is a core asset and they have the right to be informed [3]

Core Viewpoint - The company is under scrutiny from investors regarding the status of its clinical trial for TAEST16001, with concerns about transparency in communication and adherence to disclosure rules [1] Group 1: Company Response - The company emphasizes the importance of TAEST16001's clinical value and market potential, stating that it is fully committed to advancing the preparatory phase of the confirmatory clinical trial [1] - The company has previously disclosed progress in the new drug development phase and will continue to provide updates based on clinical developments in accordance with information disclosure regulations [1]

Group 1 - The core point of the article highlights the recent performance of Guangshentang, which saw a 5.03% increase in stock price, reaching 109.55 CNY per share, with a trading volume of 812 million CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 17.448 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares, with an estimated floating profit of approximately 3.7178 million CNY [2] - The China Europe Medical Health Mixed A fund was established on September 29, 2016, with a current scale of 16.977 billion CNY, achieving a year-to-date return of 21.25% and a one-year return of 8.97% [2]

Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.82%, reaching 108.92 CNY per share, with a trading volume of 916 million CNY and a turnover rate of 6.61%, resulting in a total market capitalization of 17.347 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under China Europe Fund ranks among Guangshentang's top shareholders. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating profit for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY. Year-to-date returns are 21.33%, ranking 4326 out of 8147 in its category, while the one-year return is 10.73%, ranking 5278 out of 8056 [2]

Investment Rating - The report does not explicitly state an investment rating for the industry [1] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.4% from November 3 to November 7, 2025, underperforming compared to the Wind All A index (0.63%) and the CSI 300 index (0.82%) [2][7] - The rise in flu activity was noted, with the percentage of flu-like illness (ILI) cases reported at 4.7% in the week of October 27 to November 2, 2025, indicating an increase compared to previous weeks and years [2][10] - The final overall survival (OS) results from the HARMONi-A study of Ivosidenib combined with chemotherapy for EGFR-mutant non-small cell lung cancer showed a significant improvement in OS, with a median OS of 16.8 months versus 14.1 months for the control group [2][10] Weekly Market Review - The pharmaceutical and biotechnology sector's performance was down 2.4%, with notable declines in medical research outsourcing (-4.93%), chemical preparations (-4.42%), and other biological products (-4.33%) [7][8] - The leading gainers included Hezhi China (61.1%), Wanze Shares (30.3%), and Fuxiang Pharmaceutical (23.3%), while Changshan Pharmaceutical (-20%), Yifang Bio-U (-17.8%), and Guangshengtang (-15.3%) were the biggest losers [10] Industry News and Key Company Announcements - On November 7, 2025, the final OS analysis of the HARMONi-A study was presented, showing significant results for Ivosidenib in combination with chemotherapy [10][12] - According to data from the Chinese Center for Disease Control, flu-like illness percentages in southern provinces increased to 4.6%, while northern provinces reported 5.1%, both higher than the previous week [10][12] - BeiGene reported a total revenue of $1.412 billion for Q3 2025, a 41% year-on-year increase, driven by a 51% growth in global sales of its product [12][14] - Metsera announced a merger agreement with Pfizer, with an estimated total transaction value of approximately $9 billion [12][14]